Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2017
Pharma News, 2017
Novartis names drugs chief as CEO to deliver return to growth
ZURICH (Reuters) - Novartis (NOVN.
Japan's Daiichi Sankyo denies 2016 takeover bid by AstraZeneca
TOKYO (Reuters) - Japanese drugmaker Daiichi Sankyo denied on Thursday it received a takeover bid last year from Britain’s AstraZeneca, following speculation that sent its share price soarin...
FDA approves Pfizer's leukemia drug
(Reuters) - The U.
Heptares doses first subject in Alzheimer’s drug trial
London, UK-based Heptares Therapeutics says the first healthy subject has now been dosed with its first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase I clinical study.
India's Mahendra Chemicals API plant put on FDA import alert list by Eric Palmer
The FDA issued a warning letter to India’s Mahendra Chemicals after finding a data and document disaster at its API plant in Ahmedabad.
Mylan and Biocon Herceptin biosimilar delayed by FDA for 3 months
Mylan and Biocon, which have had trouble getting to the regulatory finish line in Europe with their biosimilar of Roche’s blockbuster Herceptin because of manufacturing concerns, now face a three-mo...
FDA approves Chemo Research's treatment for Chagas disease
WASHINGTON — Earlier this week the U.
Eli Lilly to refile RA remedy to FDA
INDIANAPOLIS — Eli Lilly and Incyte Corporation on Wednesday announced that, after discussions with the U.
The Medicines Company Announces FDA Approval of VABOMERE™ (meropenem and vaborbactam)
PARSIPPANY, N.
FDA approval brings first gene therapy to the United States
The U.
AstraZeneca strikes $400 million Parkinson's drug deal with Takeda
LONDON (Reuters) - AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson’...
Lenvatinib Significantly Improved Overall Survival in Older Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer
WOODCLIFF LAKE, NJ, USA I August 28, 2017 I Eisai Inc.
23
24
25
26
27
28
29
30
31
